RENE.L Regulatory News (RENE)

1.

Name of the issuer

ReNeuron Group plc

2.

State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.2R; or (ii) a disclosure made in accordance with LR 9.8.6R(1); or (iii) in accordance with section 793 of the Companies Act 2006

(i)

3.

Name of person discharging managerial responsibilities/director

Dr. Paul Harper

4.

State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3

and identify the connected person

Director named in 3.

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest 1

Interest of person named in 3

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

Ordinary Shares

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

Person named in 3

8.

State the nature of the transaction

Placing of Ordinary Shares

9.

Number of shares, debentures or financial instruments relating to shares acquired

Acquisition of 200,000 Ordinary Shares

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

0.011%

11.

Number of shares, debentures or financial instruments relating to shares disposed

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

13.

Price per share or value of transaction

2.5 pence per Ordinary Share

14.

Date and place of transaction

9 August 2013

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

Dr. Paul Harper is interested in a total of 451,709 Ordinary Shares in the Company representing approximately 0.025% of issued Ordinary Shares.

16.

Date issuer informed of transaction

9 August 2013

17.

Date of grant

18.

Period during which or date on which it can be exercised

19.

Total amount paid (if any) for grant of the option

20.

Description of shares or debentures involved (class and number)

21.

Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise

22.

Total number of shares or debentures over which options held following notification

23.

Any additional information

See table of options held by Dr. Paul Harper below:

24.

Name of contact and telephone number for queries

Pat Huggins, Reneuron Group Plc

+44 (0)1483 302560

Name of authorised official of issuer responsible for making notification:

Patrick Huggins, Head of Finance and Company Secretary

Date of notification: 9 August 2013